FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013576541> ?p ?o ?g. }

• W2013576541 endingPage "1302" @default.
• W2013576541 startingPage "1296" @default.
• W2013576541 abstract "Desquamative gingivitis (DG) is a clinical condition characterized by red, painful, glazed, and friable gingiva, which might be a manifestation of some autoimmune mucocutaneous diseases. The time from the development of initial signs of DG to diagnosis can vary from months to years. Based on a literature search, no data concerning patients with DG without signs of autoimmune disease were available.The aim of this trial was to compare the efficacy and tolerability of monotherapy with topical tacrolimus 0.1% in pectin ointment versus clobetasol propionate 0.5% ointment in adults affected by DG.This randomized, double-blind clinical trial was conducted at the Dipartimento di Medicina Clinica e Sperimentale, Universita di Verona, Verona, Italy. Patients aged > or =18 years were selected using the department's electronic medical records based on a clinical diagnosis of moderate to severe DG. After a 2-week washout period, patients were randomly assigned to receive 2 mL of tacrolimus 0.1% in pectin (equivalent to 0.2 mg of tacrolimus) or 2 mL of clobetasol propionate 0.5% ointment (equivalent to 1 mg of clobetasol) QD for 4 weeks. Evaluations were performed before treatment (baseline), after the treatment period (week 4), and at 2 follow-up visits at weeks 6 and 8. The signs of DG (ie, erythema [atrophy] and desquamation [erosions/ulceration]) were quantified by a blinded investigator using a calculated score based on their surface extension, using a drawing in which the areas of various zones of the mouth were indicated as a percentage of the whole oral mucosa. Severity of erythema and desquamation was rated on a 4-point scale (0 = absent; 1 = involvement of <5% of surface [mild]; 2 = 5%-15% [moderate]; and 3 = >15% [severe]). The primary end point was the number of patients who achieved remission (severity score of 0) in either sign; the secondary end point was the proportions of patients achieving improvement (severity score of 0 or 1) in either sign. Before and after treatment, we measured the serum concentrations of tacrolimus and its metabolites with an immunoenzymatic assay kit. Tolerability was assessed using hematology, biochemistry, urinalysis, measurements of systolic/diastolic blood pressure and heart rate, patient interview, and spontaneous reporting.A total of 24 patients (18 women, 6 men; all white of Italian origin; age range, 21-65 years; 12 patients per treatment group) were enrolled in the study. In the tacrolimus group, 11 (91.7%) patients achieved remission of erythema and/or desquamation at weeks 4 and 6; at week 8, these rates were 9 (75.0%) and 8 (66.7%), respectively; none of the patients in the clobetasol group achieved remission of either sign at any time point (all, P < 0.001). At weeks 4, 6, and 8, significantly greater proportions of patients treated with tacrolimus had improved erythema and desquamation compared with those treated with clobetasol (all, P < 0.001). At week 4, all patients had undetectable serum tacrolimus concentrations (<1.5 microg/L). Six (50.0%) patients in the tacrolimus group reported a mild oral burning sensation, and 6 (50.0%) patients in the clobetasol group reported mild mouth dryness. No other adverse events were reported.The results of this small study suggest that topical tacrolimus 0.1 % in pectin was more effective compared with clobetasol propionate 0.5% ointment in the treatment of DG. Both treatments were generally well tolerated in the population studied." @default.
• W2013576541 created "2016-06-24" @default.
• W2013576541 creator A5025165669 @default.
• W2013576541 creator A5035112858 @default.
• W2013576541 creator A5038797557 @default.
• W2013576541 creator A5039248291 @default.
• W2013576541 creator A5058601512 @default.
• W2013576541 creator A5067811540 @default.
• W2013576541 creator A5074863074 @default.
• W2013576541 creator A5080606892 @default.
• W2013576541 date "2006-09-01" @default.
• W2013576541 modified "2023-09-24" @default.
• W2013576541 title "Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A 4-week, randomized, double-blind clinical trial" @default.
• W2013576541 cites W1548629883 @default.
• W2013576541 cites W1562075782 @default.
• W2013576541 cites W1965037455 @default.
• W2013576541 cites W1984413687 @default.
• W2013576541 cites W1991476155 @default.
• W2013576541 cites W1991636257 @default.
• W2013576541 cites W2005948180 @default.
• W2013576541 cites W2032059780 @default.
• W2013576541 cites W2036767052 @default.
• W2013576541 cites W2038141750 @default.
• W2013576541 cites W2038726289 @default.
• W2013576541 cites W2041403171 @default.
• W2013576541 cites W2052178968 @default.
• W2013576541 cites W2053429557 @default.
• W2013576541 cites W2056069965 @default.
• W2013576541 cites W2077314555 @default.
• W2013576541 cites W2080336905 @default.
• W2013576541 cites W2080483086 @default.
• W2013576541 cites W2087316971 @default.
• W2013576541 cites W2105102211 @default.
• W2013576541 cites W2118025703 @default.
• W2013576541 cites W2119920065 @default.
• W2013576541 cites W2170284002 @default.
• W2013576541 cites W2337442540 @default.
• W2013576541 cites W2605554666 @default.
• W2013576541 cites W4253233347 @default.
• W2013576541 doi "https://doi.org/10.1016/j.clinthera.2006.09.022" @default.
• W2013576541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17062302" @default.
• W2013576541 hasPublicationYear "2006" @default.
• W2013576541 type Work @default.
• W2013576541 sameAs 2013576541 @default.
• W2013576541 citedByCount "17" @default.
• W2013576541 countsByYear W20135765412015 @default.
• W2013576541 countsByYear W20135765412016 @default.
• W2013576541 countsByYear W20135765412023 @default.
• W2013576541 crossrefType "journal-article" @default.
• W2013576541 hasAuthorship W2013576541A5025165669 @default.
• W2013576541 hasAuthorship W2013576541A5035112858 @default.
• W2013576541 hasAuthorship W2013576541A5038797557 @default.
• W2013576541 hasAuthorship W2013576541A5039248291 @default.
• W2013576541 hasAuthorship W2013576541A5058601512 @default.
• W2013576541 hasAuthorship W2013576541A5067811540 @default.
• W2013576541 hasAuthorship W2013576541A5074863074 @default.
• W2013576541 hasAuthorship W2013576541A5080606892 @default.
• W2013576541 hasBestOaLocation W20135765412 @default.
• W2013576541 hasConcept C126322002 @default.
• W2013576541 hasConcept C141071460 @default.
• W2013576541 hasConcept C16005928 @default.
• W2013576541 hasConcept C168563851 @default.
• W2013576541 hasConcept C197934379 @default.
• W2013576541 hasConcept C2776110085 @default.
• W2013576541 hasConcept C2778375690 @default.
• W2013576541 hasConcept C2779121184 @default.
• W2013576541 hasConcept C2780564577 @default.
• W2013576541 hasConcept C2909675724 @default.
• W2013576541 hasConcept C2911091166 @default.
• W2013576541 hasConcept C535046627 @default.
• W2013576541 hasConcept C71924100 @default.
• W2013576541 hasConceptScore W2013576541C126322002 @default.
• W2013576541 hasConceptScore W2013576541C141071460 @default.
• W2013576541 hasConceptScore W2013576541C16005928 @default.
• W2013576541 hasConceptScore W2013576541C168563851 @default.
• W2013576541 hasConceptScore W2013576541C197934379 @default.
• W2013576541 hasConceptScore W2013576541C2776110085 @default.
• W2013576541 hasConceptScore W2013576541C2778375690 @default.
• W2013576541 hasConceptScore W2013576541C2779121184 @default.
• W2013576541 hasConceptScore W2013576541C2780564577 @default.
• W2013576541 hasConceptScore W2013576541C2909675724 @default.
• W2013576541 hasConceptScore W2013576541C2911091166 @default.
• W2013576541 hasConceptScore W2013576541C535046627 @default.
• W2013576541 hasConceptScore W2013576541C71924100 @default.
• W2013576541 hasIssue "9" @default.
• W2013576541 hasLocation W20135765411 @default.
• W2013576541 hasLocation W20135765412 @default.
• W2013576541 hasLocation W20135765413 @default.
• W2013576541 hasOpenAccess W2013576541 @default.
• W2013576541 hasPrimaryLocation W20135765411 @default.
• W2013576541 hasRelatedWork W1984006272 @default.
• W2013576541 hasRelatedWork W2035876935 @default.
• W2013576541 hasRelatedWork W2083822655 @default.
• W2013576541 hasRelatedWork W2153652012 @default.
• W2013576541 hasRelatedWork W2334475842 @default.
• W2013576541 hasRelatedWork W2402132108 @default.
• W2013576541 hasRelatedWork W2480721245 @default.
• W2013576541 hasRelatedWork W304587184 @default.

• next